Tumor Biology

, Volume 35, Issue 7, pp 6619–6625 | Cite as

Clinical significance of serum tenascin-C levels in breast cancer

  • D. Tastekin
  • F. Tas
  • S. Karabulut
  • D. Duranyildiz
  • M. Serilmez
  • M. Guveli
  • S. Vatansever
Research Article


Tenascin-C (TNC) is a key molecule in tissue remodeling, and high levels are observed in many diseases, including heart failure, thrombosis, atherosclerosis, and cancer. High TNC expression by immunohistochemical analysis has been shown in invasive and metastasizing tissues from a variety of cancers, including colon, lung, brain, and breast. This study was conducted to investigate the serum level of TNC in breast cancer patients and its relationship with tumor progression and known prognostic parameters. Ninety-six breast cancer patients were enrolled into the study. Serum samples were obtained on first admission before adjuvant and metastatic treatments were given and at follow-up. Serum TNC levels were determined by the solid-phase sandwich enzyme-linked immunosorbent assay (ELISA) method. Median age of diagnosis was 48 years old (range, 29–80). Thirty-seven (39 %) patients had metastatic breast cancer. The mean TNC levels were found to be significantly higher in patients with breast cancer (344.1 ± 42.4 pg/mL) compared to those in healthy controls (137.2 ± 26.8 pg/mL) (p = 0.005). Serum TNC level in grade 3 tumors was found to be significantly higher than in grades 1–2 tumors (p = 0.04). No correlation was detected between serum TNC levels and other prognostic parameters analyzed, including presence of metastasis, lymph node involvement, and tumor size. Serum TNC level had no significantly adverse effect on survival in univariate and multivariate analyses (p = 0.65 and p = 0.85, respectively). In conclusion, although serum TNC levels are elevated, it has no predictive or prognostic roles on survival in breast cancer patients.


Tenascin-C Breast cancer Prognosis 


Conflicts of interest



  1. 1.
    Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenascin-C biology. Cell Mol Life Sci. 2011;68(19):3175–99.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Kusagawa H, Onoda K, Namikawa S, Yada I, Okada A, Yoshida T, et al. Expression and degeneration of tenascin-C in human lung cancers. Br J Cancer. 1998;77(1):98–102.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer. 2003;98(11):2430–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K, et al. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer. 1998;78(11):1507–13.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244(2):143–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol. 2005;37(5):1066–83.CrossRefPubMedGoogle Scholar
  7. 7.
    Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17(7):867–74.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Guttery DS, Shaw JA, Lloyd K, Pringle JH, Walker RA. Expression of tenascin-C and its isoforms in the breast. Cancer Metastasis Rev. 2010;29(4):595–606.CrossRefPubMedGoogle Scholar
  9. 9.
    Ferguson JE, Schor AM, Howell A, Ferguson MW. Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. Differentiation. 1990;42(3):199–207.CrossRefPubMedGoogle Scholar
  10. 10.
    Howeedy AA, Virtanen I, Laitinen L, Gould NS, Koukoulis GK, Gould VE. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Investig. 1990;63(6):798–806.PubMedGoogle Scholar
  11. 11.
    Gould VE, Koukoulis GK, Virtanen I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differ Dev. 1990;32(3):409–16.CrossRefPubMedGoogle Scholar
  12. 12.
    Jahkola T, Toivonen T, Nordling S, von Smitten K, Virtanen I. Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur J Cancer. 1998;34(11):1687–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Goepel C, Buchmann J, Schultka R, Koelbl H. Tenascin-A marker for the malignant potential of preinvasive breast cancers. Gynecol Oncol. 2000;79(3):372–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res. 1995;1(9):1035–41.PubMedGoogle Scholar
  15. 15.
    Jahkola T, Toivonen T, von Smitten K, Blomqvist C, Virtanen I. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer. 1996;69(6):445–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Shoji T, Kamiya T, Tsubura A, Hamada Y, Hatano T, Hioki K, et al. Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res. 1993;55(3):295–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer. 2002;38(18):2362–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res. 2004;10(7):2491–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, et al. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 2008;14(17):5555–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Iskaros BF, Hu X, Sparano JA, Fineberg SA. Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. J Surg Oncol. 1998;68(2):107–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Tökés AM, Hortoványi E, Csordás G, Kulka J, Mózes G, Hatalyák A, et al. Immunohistochemical localisation of tenascin in invasive ductal carcinoma of the breast. Anticancer Res. 1999;19(1A):175–9.PubMedGoogle Scholar
  22. 22.
    Moch H, Torhorst J, Dürmüller U, Feichter GE, Sauter G, Gudat F. Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. Pathol Res Pract. 1993;189(5):510–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, et al. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res. 2005;25(1B):489–95.PubMedGoogle Scholar
  24. 24.
    Burchardt ER, Hein R, Bosserhoff AK. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin Exp Dermatol. 2003;28(5):515–20.CrossRefPubMedGoogle Scholar
  25. 25.
    Pauli C, Stieber P, Schmitt UM, Andratschke M, Hoffmann K, Wollenberg B. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck. Anticancer Res. 2002;22(5):3093–7.PubMedGoogle Scholar
  26. 26.
    Riedl S, Bodenmüller H, Hinz U, Holle R, Möller P, Schlag P, et al. Significance of tenascin serum level as tumor marker in primary colorectal carcinoma. Int J Cancer. 1995;64(1):65–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, Stupp R, et al. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Int J Cancer. 2008;122(11):2454–61.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • D. Tastekin
    • 1
  • F. Tas
    • 1
  • S. Karabulut
    • 1
  • D. Duranyildiz
    • 2
  • M. Serilmez
    • 2
  • M. Guveli
    • 3
  • S. Vatansever
    • 1
  1. 1.Department of Medical Oncology, Oncology InstituteIstanbul UniversityIstanbulTurkey
  2. 2.Department of Basic Oncology, Oncology InstituteIstanbul UniversityIstanbulTurkey
  3. 3.Department of Radiation Oncology, Oncology InstituteIstanbul UniversityIstanbulTurkey

Personalised recommendations